Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: A 24-week randomized, double-blind, placebo-controlled trial
Journal of Clinical Psychiatry, Volume 70, No. 8, Year 2009
Notification
URL copied to clipboard!
Description
Objective: This study evaluates the efficacy of agomelatine, the first antidepressant that is an agonist at MT1/MT2 receptors and an antagonist at 5-HT2C receptor, in the prevention of relapse of depression following successful response. Method: Patients with DSM-IV-TR major depressive disorder who responded to an 8- or 10-week course of agomelatine 25- or 50-mg daily treatment were randomly assigned to receive continuation treatment with agomelatine (n = 165) or placebo (n = 174) during a 24-week, randomized, double-blind treatment period. The main outcome measure was time to relapse during the double-blind treatment period. The cumulative probability of relapse was calculated using the Kaplan-Meier method of survival analysis. The study was conducted from February 2005 to February 2007. Results: During the 6-month evaluation period, the incidence of relapse was significantly lower in patients who continued treatment than in those switched to placebo (P = .0001). The cumulative relapse rate at 6 months for agomelatine-treated patients was 21.7%; that for placebo-treated patients was 46.6%. Agomelatine was also superior to placebo in preventing relapse in the subset of patients with baseline 17-item Hamilton Depression Rating Scale total score ≥ 25. Measures of tolerability and safety of both doses of agomelatine were similar to placebo. No pattern of early relapse or adverse events suggestive of withdrawal symptoms was obtained after abrupt cessation of agomelatine. Conclusions: The findings are important in 2 respects. First, agomelatine is an effective and safe antidepressant continuation therapy, which confirms efficacy seen in short-term studies. Second, few early relapses were observed in the patient group switched to placebo: the survival curve for placebo separated gradually from that of patients taking agomelatine. We suggest this reflects solely the underlying properties of the illness, which is only possible due to the lack of discontinuation syndrome after agomelatine withdrawal. It underlines the novel clinical profile of agomelatine, which quite likely reflects its innovative pharmacology. Trial Registration: isrctn.org Identifier: ISRCTN53193024. © Copyright 2009 Physicians Postgraduate Press, Inc.
Authors & Co-Authors
Goodwin, Guy M.
United Kingdom, Oxford
University of Oxford
Emsley, Robin Alexander
South Africa, Stellenbosch
Stellenbosch University
Rembry, Sandra
France, Courbevoie
Iris Institut de Recherches Internationales Servier
Rouillon, Frederick
France, Paris
Centre Hospitalier Sainte-anne
Statistics
Citations: 190
Authors: 4
Affiliations: 4
Identifiers
Doi:
10.4088/JCP.08m04548
ISSN:
01606689
Research Areas
Disability
Health System And Policy
Mental Health
Study Design
Cohort Study